3-(substituted amino)-pyrazolo[3,4-d]pyrimidines as EphB and VEGFR2 kinase inhibitors

Details for Australian Patent Application No. 2006319401 (hide)

Owner Novartis AG

Inventors Schmiedeberg, Niko; Holzer, Philipp; Imbach, Patricia; Furet, Pascal

Agent Davies Collison Cave

Pub. Number AU-A-2006319401

PCT Pub. Number WO2007/062805

Priority 0524436.3 30.11.05 GB

Filing date 28 November 2006

Wipo publication date 7 June 2007

International Classifications

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

12 June 2008 PCT application entered the National Phase

  PCT publication WO2007/062805 Priority application(s): WO2007/062805

3 November 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006319411-Neramexane modified release matrix tablet

2006319383-Prodrug ERbeta-selective substances, methods for the production thereof and pharmaceutical compositions containing said compounds